Abstract
Anti-cancer drug development is a major area of research. Monitoring of response to newer anti-cancer drugs has undergone an evolution from structural imaging modalities to targeting functional metabolic activity at cellular level to better define responsive and non-responsive cancerous tissue. This review article highlights the contribution of Positron Emission Tomography (PET) in this field. PET holds a promising role in the future by providing us information pertaining to the drugs effectiveness early in the course of therapy, so that side effects and expenses can be reduced substantially. PET has been used to measure changes in drug induced metabolism, cellular proliferation and tissue perfusion. Also changes induced by immuno-modulating drugs such as apoptosis, telomere activity, growth factor levels and many more can be studied using specific radiolabelled PET tracers whereas conventional imaging modalities which detect changes in tumor size and residual tissue histopathology may not prove useful in such scenario. In future, most PET scanners will be replaced by Hybrid PET-CT scanners, which provide functional and structural information in the same setting. In addition, PET-CT improves characterization of equivocal lesions and decreases interobserver variability. The most important recent patents concerning role of PET in drug development have been presented.
Keywords: PET, PET-CT, drug development, therapy response
Recent Patents on Anti-Cancer Drug Discovery
Title: PET in Anti-Cancer Drug Development and Therapy
Volume: 2 Issue: 3
Author(s): Rakesh Kumar and Neena Lal
Affiliation:
Keywords: PET, PET-CT, drug development, therapy response
Abstract: Anti-cancer drug development is a major area of research. Monitoring of response to newer anti-cancer drugs has undergone an evolution from structural imaging modalities to targeting functional metabolic activity at cellular level to better define responsive and non-responsive cancerous tissue. This review article highlights the contribution of Positron Emission Tomography (PET) in this field. PET holds a promising role in the future by providing us information pertaining to the drugs effectiveness early in the course of therapy, so that side effects and expenses can be reduced substantially. PET has been used to measure changes in drug induced metabolism, cellular proliferation and tissue perfusion. Also changes induced by immuno-modulating drugs such as apoptosis, telomere activity, growth factor levels and many more can be studied using specific radiolabelled PET tracers whereas conventional imaging modalities which detect changes in tumor size and residual tissue histopathology may not prove useful in such scenario. In future, most PET scanners will be replaced by Hybrid PET-CT scanners, which provide functional and structural information in the same setting. In addition, PET-CT improves characterization of equivocal lesions and decreases interobserver variability. The most important recent patents concerning role of PET in drug development have been presented.
Export Options
About this article
Cite this article as:
Kumar Rakesh and Lal Neena, PET in Anti-Cancer Drug Development and Therapy, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (3) . https://dx.doi.org/10.2174/157489207782497190
DOI https://dx.doi.org/10.2174/157489207782497190 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Anti-Cancer Agents in Medicinal Chemistry ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Functions of S100 Proteins
Current Molecular Medicine Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Membrane Interacting Peptides: A Review
Current Protein & Peptide Science Cellular Photodynamic Toxicity of Hematoporphyrin in Various Nanocarrier Systems
Current Nanoscience 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Brain Drug Delivery System: An Overview
Current Drug Therapy Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery